Advertisement

Topics

STAT Plus: Pharmalittle: A type 2 diabetes win for Novo Nordisk; FDA’s research on drug ads questioned

09:22 EDT 17 Aug 2017 | STAT

Novo Nordisk's semaglutide, combined with metformin, successfully reduced glucose levels when tested head-to-head against a competitor from Eli Lilly.

Original Article: STAT Plus: Pharmalittle: A type 2 diabetes win for Novo Nordisk; FDA’s research on drug ads questioned

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Pharmalittle: A type 2 diabetes win for Novo Nordisk; FDA’s research on drug ads questioned"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...